Q3 Earnings Forecast for ETRA Issued By HC Wainwright

Electra Therapeutics, Inc. (NASDAQ:ETRA) – Equities research analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Electra Therapeutics in a research note issued on Monday, October 26th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.56) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Electra Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Electra Therapeutics’ Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.70) EPS and FY2027 earnings at ($2.48) EPS.

Several other analysts have also recently issued reports on ETRA. Jefferies Financial Group started coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price objective on the stock. JPMorgan Chase & Co. began coverage on Electra Therapeutics in a report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. TD Cowen initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued a “buy” rating on the stock. Finally, Zacks Research raised Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $33.50.

Electra Therapeutics Trading Up 1.8%

Shares of ETRA stock opened at $8.52 on Wednesday. Electra Therapeutics has a 52 week low of $8.26 and a 52 week high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Carl Gordon purchased 1,333,333 shares of the business’s stock in a transaction on Monday, September 21st. The shares were bought at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the purchase, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the business’s stock in a transaction on Monday, September 21st. The stock was acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.